Clene Inc (CLNN)

In January 2026, Clene announced an oversubscribed registered direct offering of over $28 million, priced above market. In March 2026, Clene reported its full-year 2025 financial results, with a net loss of $26.2 million and cash and cash equivalents of $5.2 million as of December 31, 2025, and announced an upcoming Type C meeting with the FDA to discuss biomarker and survival data for CNM-Au8 in ALS. In May 2026, Clene announced a $7 million underwritten offering of common stock and received positive feedback from the FDA regarding the potential for an accelerated approval pathway for CNM-Au8 in ALS, leading to a stock increase. As of May 5, 2026, the share price was $6.58, representing an increase of 130.88% over the past year.

Information specifically detailing the demand seasonality for Clene, Inc.'s products and services is not available.

Clene, Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology (CSN) therapeutics to improve mitochondrial health and neuronal function for neurodegenerative diseases like ALS, Parkinson's, and MS. Their lead drug candidate, CNM-Au8, is being studied in clinical trials for these conditions. The company also develops other products, including CNM-AgZn17, CNM-ZnA; rMetx, and KHC46, as well as a gold-platinum CSN therapeutic called NM-PtAu7.

Clene Inc. is headquartered in Salt Lake City, Utah, with its research and development (R&D) and manufacturing operations located in Maryland, United States.

Clene's brand reputation has been positively impacted by clinical progress, particularly with CNM-Au8, and positive FDA feedback, which boosted sentiment. CNM-Au8 has shown strong biomarker and safety results in clinical trials. However, the company's disclosed doubts about its ability to continue as a going concern could affect its long-term reputation among investors.

Clene Inc. has 29 institutional owners and shareholders holding a total of 1,938,685 shares, with approximately 23.28% of the stock held by institutions. Insiders hold 28.30% of the stock. In the past three months, Clene insiders have sold $1,439,351.00 in company stock, with no insider buying reported. Major institutional owners include SymBiosis Capital Partners, LLC, Scoggin Management Lp, and Vanguard Group Inc, among others.